Anthem Biosciences IPO
IPO Listing Details
- Listing Date
21 Jul 2025
- Listing Price
₹723.10
- Listing Change
26.86%
- Last Traded Price
₹699.45
Anthem Biosciences IPO Details
-
Open Date
14 Jul 2025
-
Close Date
16 Jul 2025
-
Listing Date
21 Jul 2025
- IPO Price Range
₹ 540 to ₹570
- IPO Size
₹ 3,395 Cr
- Listing Exchange
BSE, NSE
Anthem Biosciences IPO Timeline
Anthem Biosciences IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 14-Jul-25 | 0.39 | 1.64 | 0.62 | 0.77 |
| 15-Jul-25 | 0.62 | 10.26 | 2.21 | 3.48 |
| 16-Jul-25 | 192.80 | 44.70 | 5.98 | 67.42 |
Last Updated: 24 July 2025 5:28 PM by 5paisa
Anthem Biosciences Ltd., founded in 2006, is a Bengaluru-based Contract Research, Development, and Manufacturing Organisation (CRDMO). It specialises in drug discovery, development, and production for both biologics and small molecules. Anthem serves over 550 global customers, including large pharmaceutical companies and biotech firms across the US, Europe, and Japan. Its offerings span APIs, peptides, enzymes, biosimilars, and fermentation-based actives. The company has 196 active projects and holds 8 patents (including pending applications).
Chairman & MD: Ajay Bhardwaj
Established: 2006
Peers
Syngene International Ltd
Sai Life Sciences Limited
Cohance Lifesciences Limited
Divi’s Laboratories Limited
Anthem Biosciences Objectives
While Anthem Biosciences' issue is structured as an IPO, it is essentially a 100% Offer for Sale (OFS), with promoters and early investors exiting and no fresh capital being raised for the company’s business operations.
Anthem Biosciences IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹3,395.00 Cr |
| Offer For Sale | ₹3,395.00 Cr |
| Fresh Issue | Nil |
Anthem Biosciences IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,040 |
| Retail (Max) | 13 | 338 | ₹1,82,520 |
| S-HNI (Min) | 14 | 364 | ₹1,96,560 |
| S-HNI (MAX) | 67 | 1,742 | ₹9,40,680 |
| B-HNI (Min) | 68 | 1,768 | ₹9,54,720 |
Anthem Biosciences IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB | 192.80 | 1,18,83,334 | 2,29,10,95,976 | 1,30,592.47 |
| NII (HNI) | 44.70 | 89,12,500 | 39,84,26,912 | 22,710.33 |
| bNII (bids above ₹10L) | 51.66 | 59,41,667 | 30,69,18,534 | 17,494.36 |
| sNII (bids below ₹10L) | 30.80 | 29,70,833 | 9,15,08,378 | 5,215.98 |
| Retail | 5.98 | 2,07,95,833 | 12,42,99,214 | 7,085.06 |
| Total** | 67.42 | 4,17,50,321 | 2,81,49,30,794 | 1,60,451.06 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
Anthem Biosciences IPO Anchor Allocation
| Anchor Bid Date | July 11, 2025 |
| Shares Offered | 1,78,24,999 |
| Anchor portion Size (In ₹ Cr.) | 1,016.02 |
| Anchor lock-in period end date for 50% shares (30 Days) | August 16, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | October 15, 2025 |
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 1133.99 | 1483.07 | 1930.29 |
| EBITDA | 446.05 | 519.96 | 683.78 |
| PAT | 385.19 | 367.31 | 451.26 |
| Particulars (in Rs. Crores)] | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Assets | 2014.46 | 2398.11 | 2807.58 |
| Share Capital | 114.10 | 111.82 | 111.82 |
| Total Borrowings | 125.06 | 232.53 | 108.95 |
| Particulars (in Rs. Crores | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | 305.99 | 140.15 | 418.34 |
| Net Cash Generated From / (used in) investing activities | -376.02 | -221.46 | -152.11 |
| Net Cash Generated From / (used in) financing activities | 63.97 | -77.18 | -133.60 |
| Net Increase (Decrease) In Cash And Cash Equivalents | -6.06 | -158.49 | -132.62 |
Strengths
1. Comprehensive CRDMO platform with global presence
2. Over 550 active customers, including major pharmaceutical firms
3. High R&D and manufacturing capabilities with an IP portfolio
4. Growing revenue and profitability metrics
Weaknesses
1. No fresh issue; funds do not strengthen the balance sheet
2. High dependence on global clients and export markets
3. High capital expenditure is seen through consistently negative cash flow from investing activities.
4. Dependence on borrowing, with total debt peaking at ₹232.53 Cr in FY24.
Opportunities
1. Expansion in Europe and the Asia-Pacific markets
2. Patented innovations across multiple therapeutic verticals
3. Biotech boom and rising global outsourcing demand
4. International business is seeing consistent growth
Threats
1. Currency fluctuations are impacting export revenues
2. Heightened regulatory scrutiny and IP risks
3. Competition from global CRO/CDMO players
4. Contingent scenario: for example, Covid
1. One-stop CRDMO platform spanning discovery to commercialisation
2. Strong global client network and IP assets
3. Consistent revenue growth and operational efficiency
3. Market leadership in fermentation-based APIs
1. India's CRDMO market is experiencing rapid growth, driven by global outsourcing and the need for innovation support from pharma companies.
2. Increasing R&D budgets, focus on biologics
3. Government support for innovation has further bolstered this segment.
4. Anthem stands at the centre of this transformation with an integrated, scalable business model.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
The Anthem Biosciences IPO opens on July 14 and closes on July 16, 2025.
The total offer of Anthem Biosciences IPO is worth ₹3,395.00 crore.
The IPO price band of Anthem Biosciences IPO is fixed between ₹540 to ₹570 per share.
To apply for Anthem Biosciences IPO, follow the steps given below:
- Login to your 5paisa account and select the issue in the current IPO section
- Enter the number of lots and the price at which you wish to apply for the Anthem Biosciences IPO
- Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange
You will receive the mandate notification to block funds in your UPI app
The minimum lot size of Anthem Biosciences IPO is 26 shares with a minimum retail investment of ₹14,040.
The allotment date of Anthem Biosciences IPO is expected to be finalised on July 17, 2025.
The tentative listing date of Anthem Biosciences IPO is July 21, 2025, on the NSE, BSE platforms.
JM Financial Limited is the book-running lead manager of Anthem Biosciences IPO.
This is a complete offer for sale, meaning the IPO proceeds will go to existing shareholders. The company is not raising fresh capital through this issue.
Anthem Biosciences Contact Details
Anthem Biosciences Ltd.
No. 49, F1 & F2, Canara Bank Road
Bommasandra Industrial Area, Phase 1,
Bommasandra,
Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/
Anthem Biosciences IPO Register
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: anthem.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/
Anthem Biosciences IPO Lead Manager
Jm Financial Limited
Citigroup Global Markets India Private Limited
J.P. Morgan India Private Limited
Nomura Financial Advisory And Securities (India) Pvt Ltd